Stocks · News reference

Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

Aug 14, 2026, 5:15 PMBenzinga Newsdesk

Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 12, 2026, 10:22 PMSEC EDGAR
8-K filing — OnKure Therapeutics, Inc. (OKUR)
Filed: 2026-08-13 AccNo: 0001193125-26-347315 Size: 158 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
OKUR
BenzingaAug 4, 2026, 9:40 PMBenzinga Newsdesk
CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share
Read original at benzinga
OKUR
BenzingaAug 4, 2026, 9:22 PMBenzinga Newsdesk
OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners
https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm
Read original at benzinga
OKUR